Announcement of selection for an AMED drug discovery basic technology project for the realization of next-generation treatment and diagnosis entitled “Innovative Next Generation of Oligonucleotide Therapeutics (INGOT)”

Announcement of selection for an AMED drug discovery basic technology project for the realization of next-generation treatment and diagnosis entitled “Innovative Next Generation of Oligonucleotide Therapeutics (INGOT)”

This time, we are the core business of “Drug discovery basic technology project for realization of next-generation treatment and diagnosis (RNA target drug discovery technology)” adopted by the Japan Agency for Medical Research and Development (AMED). To work with Tokyo Medical and Dental University, Tokyo University of Science, and Nippon Shokubai Co., Ltd. to develop a chemical synthesis technology for boranophosphate antisense nucleic acid (PB-ASO) in which the steric chemistry (clarity) of the phosphorus atom is optimally controlled. I will inform you now.

See below for details.

About "Development of basic drug discovery technology for the realization of next-generation treatment and diagnosis (Development of RNA-targeted drug discovery technology)"